Kolkata, Feb 20: Following the International Epilepsy Day, on 8th February, MSN Laboratories Pvt. Ltd. (MSN), India’s leading integrated pharmaceutical research company, organized an Epilepsy Awareness session.

Dr. R V Nagarajan, Chairman – National Neuroscience Research Committee & Task Force, Ministry of Health & Family Welfare; Dr. Suryaprabha, Addl. Professor of Neurology Department – Nizam’s Institute of Medical Sciences and Dr. Pranathi Gutta, Consultant Paediatric Neurology – KIMS Hospitals attended the session as guest speakers and highlighted the treatment burden, myths and facts about the disease.

The session focused on the social stigma and cost burden attached to Epilepsy though it is the second most common Neurological disorder in the world today.

The session ended with the announcement of BRIVANEXT™, to be launched after the patent expiry (i.e. 22nd February). Brivanext will be one of the most affordable therapeutic option and will be available in Tab & Injectable form across pharmacies from 22nd February.

India approximately has over 1.2 crore Patients who suffer from various Epileptic forms with prevalence both in juveniles and adults. As per the survey, the lack of awareness of the disease and the availability of affordable treatment options were the primary cause for steady incline of Epilepsy cases in India. Currently, Brivaracetam tablet is available in India by Innovator through its in-licensing partner with a cost of approx 106 INR per tablet.

Commenting on the launch of BRIVANEXT, Bharat Reddy, Executive Director – MSN Group, said “MSN has always played a significant role in making branded generics affordable. Like our other products we are sure that BRIVANEXT would support the patient with affordability and would give more choices to the doctors. We as a company believe that any medicine should be within reach and affordable to all.”

Being a new age molecule Brivaracetam has high & selective affinity for SV2A protein 15-30 times higher in comparison with Levetiracetam. MSN has developed the Active Pharmaceutical Ingredient (API) & the finished dosage formulation (FDF) of BRIVANEXT through its in-house state of the art R&D center. The development is truly indigenous right from conceptualization, API development to FDF.

The API & FDF of BRIVANEXT matches to the quality of the innovator and has received the mandatory DCGI clearance. MSN will launch post patent expiry BRIVANEXT in the tablet and IV dosage form in India and is the only company to file an ANDA for liquid dosage form in US as well. (UNI)